Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update
Theratechnologies Faces Potential Supply Disruption For Its Top Selling Drug, Warns of Revenue Impact Due To Manufacturing Delays
Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV in Early 2025
Theratechnologies to Present at Upcoming Investor Conferences in September
Positive Signs As Multiple Insiders Buy Theratechnologies Stock
Theratechnologies Second Quarter 2024 Earnings: Beats Expectations
Theratechnologies: Strong Q2 Performance and Positive Outlook Justify Buy Rating
JonesTrading Maintains Theratechnologies(THTX.US) With Buy Rating, Maintains Target Price $3
JonesTrading analyst Justin Walsh maintains $Theratechnologies(THTX.US)$ with a buy rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 36.2%
Earnings Call Summary | Theratechnologies(THTX.US) Q2 2024 Earnings Conference
Theratechnologies Inc. (THTX) Q2 2024 Earnings Call Transcript
HIV Medicine Maker Theratechnologies 'Wraps Up Strong Second Quarter,' Stock Soars
Theratechnologies | 6-K: Report of foreign private issuer (related to financial reporting)
Theratechnologies Swings to Q2 Profit as Revenue Rises 25%; Confirms FY24 Guidance
Theratechnologies Celebrates Profitable Q2 With Revenue Surge
Theratechnologies Reiterates FY24 Revenue Guidance Range Of $87M-$90M Vs. $87.88M Estimate
Theratechnologies Q2 Sales $22.02M Beat $21.71M Estimate, Company Ended Q2 With $36.03M In Cash
Theratechnologies: Interim Fincl Statements Have Been Prepared Assuming the Co Will Continue as a Going Concern >TH.T
Theratechnologies: Material Uncertainty That Raised Substantial Doubt About Ability to Continue as Going Concern Was Alleviated Effective From 2Q Results
Theratechnologies Expects Existing Cash and Cash Equivalents as of May 31, Together With Cash Generated Sufficient to Fund Oper Expenses and Debt Obligations for at Least Next 12 Mos
Theratechnologies Brief: Fiscal 2024 Revenue Guidance Confirmed Between US$87 and $90 Million and an Adjusted EBITDA in the Range of $13 to $15 Million